About: Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial
Creator	Cinatl, J Rabenau, H Berger, A Bojkova, D Hoehl, S Kortenbusch, M
Source	MedRxiv
abstract	Objective: To analyze the efficacy of Hydroxychloroquine (HCQ) plus standard of care (SOC) compared with SOC alone in reducing disease progression in Mild COVID-19 Design: A single centre, open label randomized controlled trial Place and Duration: Pulmonology department, Pak emirates Military Hospital (PEMH) from 10 April 2020 to 31 May 2020. Methodology: Five hundred patients of both genders having age between 18-50 years who were PCR positive and had Mild COVID-19 were selected. Patients assigned to standard dose of HCQ (400mg 12 hourly day 1 then 200mg 12 hrly for next 4 days) plus SOC were 349 while 151 patients received SOC comprising of Vit C, Vit D, and Zinc only (control group). Primary outcome was progression of disease while secondary outcome was PCR negativity on day 7 and 14. The results were analyzed on SPSS version 23. P value <0.05 was considered significant. Results: Median age of intervention group (34 + 11.778 years) and control group (34 + 9.813 years). Disease progressed in 16 patients, 11 (3.15%) were in intervention group as compared to 5 (3.35%) in control group, (p value = 0.865). PCR negativity in intervention and control groups were (day 7, 182 (52.1%) vs. 54 (35.7%) (p value = 0.001), (day 14, 244 (69.9%) vs. 110 (72.8%) (p value = 0.508). Consecutive PCR negativity at day 7 and 14 was observed in 240 (68.8%) in intervention group compared to 108 (71.5%) in control group. (p value = 0.231). Conclusion: Addition of HCQ to standard of care treatment in Mild COVID-19 neither prevents disease progression nor is it significantly associated with successive PCR negativity on day 7 and 14.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1101/2020.07.30.20165365
has license	medrxiv
sha1sum (hex)	2a524bc57aa0d8463d3ac70ce0373356884cdc3b
schema:url	https://doi.org/10.1101/2020.07.30.20165365
resource representing a document's title	Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial
resource representing a document's body	covid:2a524bc57aa0d8463d3ac70ce0373356884cdc3b#body_text
is schema:about of	named entity 'centre' named entity 'emirates' named entity 'Pulmonology' named entity 'Derivatives' named entity 'DISEASE PROGRESSION' named entity 'COVID-19' covid:arg/2a524bc57aa0d8463d3ac70ce0373356884cdc3b named entity 'SOC' named entity 'care' named entity 'Synthesis' named entity 'SOC' named entity 'open label' named entity 'medRxiv' named entity 'preprint' named entity 'medRxiv' named entity 'preprint' named entity 'PCR' named entity 'constitutional symptoms' named entity 'HCQ' named entity '69.8%' named entity 't-test' named entity 'HCQ' named entity 'sore throat' named entity 'body aches' named entity 'preprint' named entity 'COVID-19' named entity 'medRxiv' named entity 'Military Hospital' named entity 'body aches' named entity 'anosmia' named entity 'medRxiv' named entity 'chronic health' named entity 'chloroquine' named entity 'asymptomatic patients' named entity 'RT-PCR' named entity 'Absolute lymphocyte count' named entity 'peer review' named entity 'preprint' named entity 'preprint' named entity 'ALC' named entity 'Covid-19' named entity 'preprint' named entity 'written consent' named entity 'medRxiv' named entity 'preprint' named entity 'viral particles' named entity 'allergy' named entity 'exponential rise' named entity 'COVID' named entity 'categorical data' named entity 'X-ray' named entity 'cytokine storm' named entity 'PCR' named entity 'fatigue' named entity 'HCQ' named entity 'PCR' named entity 'SOC' named entity 'viral load' named entity 'Zinc' named entity 'CRP' named entity 'peer review' named entity 'supportive care' named entity 'open label' named entity 'morbidity' named entity 'preprint' named entity 'control group' named entity 'chloroquine' named entity 'headache' named entity 'supportive treatment' named entity 'Standard of care' named entity 'peer review' named entity 'HCQ' named entity 'HCQ' named entity 'SPSS' named entity 'HCQ' named entity 'HCQ' named entity 'preprint' named entity 'Pakistan' named entity 'HCQ' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software